Evolving landscape: Exploring the intersection of COVID-19 Vaccines, Microbiome, and Long-Term Safety | ||
| Archives of Pharmaceutical Sciences Ain Shams University | ||
| Articles in Press, Accepted Manuscript, Available Online from 15 November 2025 | ||
| Document Type: Review Article | ||
| DOI: 10.21608/aps.2025.398216.1237 | ||
| Authors | ||
| Sondos Saied Ahmed* 1; Nagwa Ali Sabri2; Amal A. Elkholy3 | ||
| 1Clinical Pharmacy,Msc Student | ||
| 2Prof and Head of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt | ||
| 3Clinical pharmacy department, Faculty of pharmacy, Ainshams university, Cairo, Egypt | ||
| Abstract | ||
| The COVID-19 pandemic has accelerated vaccine development and deployment, with intake of over 13 billion doses globally as of 2023. While these vaccines demonstrate remarkable efficacy in reducing severe outcomes, emerging evidence suggests complex interactions between vaccination, gut microbiome composition, and long-term immune responses. This review investigates and shows the understanding of how vaccines may influence health and immune function through microbiome changes, especially for enhancing vaccine efficacy and public health outcomes. The interaction of microbial ecology and vaccine pharmacology presents novel opportunities for personalized immunization strategies but requires rigorous longitudinal studies to establish causal mechanisms. We address key challenges like vaccine distribution and safety concerns, offering recommendations for effective risk communication and collaborative research. Ultimately, the continuous evaluation of vaccine safety, microbiome interactions, and long-term effects is essential for optimizing global vaccination efforts and evidence-based decision-making. KEYWORDS COVID-19 vaccines, Microbiome-Vaccine interactions, Vaccine Pharmacovigilance, COVID-19 Immunogenicity, Gut microbiota Impact, Adverse Events following immunization (AEFI), Immunogenicity | ||
| Keywords | ||
| KEYWORDS COVID-19 vaccines; Microbiome-Vaccine interactions; Vaccine Pharmacovigilance; COVID-19 Immunogenicity; Gut microbiota Impact; Adverse Events following immunization (AEFI); Immunogenicity | ||
|
Statistics Article View: 1 |
||
